Carl Heneghan In 2019, EBM Live set out to identify and fix some of the problems with how research evidence is developed and disseminated to end-users. Issues outlined in the
I recently attended the Evidence-Based Medicine Live19 conference at Oxford University where Professor Isabella Boutron from the Paris Descartes University presented a lecture entitled ‘Spin or Distortion of Research Results’.
Evidence-based medicine (EBM) seems to lack explicit considerations of the properties of the phenomena that we want evidence about.
Good appealing tradenames stick -“Trick”- the memory of both patients and prescribers (the actual end-users). Tradenames reflect whether medications are being primarily marketed to practitioners or to the public.
How do we consider diseases nowadays and how do we develop and interpret evidence on this? The questions was introduced in an earlier blog because Evidence-based medicine (EBM) does not
“It is not our differences that divide us; but the inability to recognize, accept and celebrate those differences” said writer Audre Lorde. For decades, there has been a gap between
But too much freedom can be a bad thing when it comes to analysis. The danger is that we may use the trial data to help us choose a method that gives us the answer we want.
Today, how do we consider diseases and how do we develop and interpret evidence on this? How does modern medicine actually consider interrelated medical fundamentals such as disease, diagnosis, risk factor, existential condition, and problem?
For supposedly clever people, we academics are complete mugs. Not only do we give away our research for publishers to make a profit1, our institutions pay hefty subscriptions just to access it, or pay even more if we want to make it freely available.
This social pressure for “unmet medical needs” is, in many times, used as an argument for faster drugs approvals pathways. Access to new technologies is important but a balance between access, the cost of clinical drug trials and ensuring robust evidence, “relevant, replicable, and accessible to end users” is required.
The Summer School invites EBHC students, supervisors, consumers and leading evidence-based experts into the surroundings of Kellogg College, University of Oxford. Spanning three weeks this unique experience offers: EBHC modules;
As a full-time teacher, it is relatively rare that I get the opportunity to go to teacher conferences, let alone the chance to attend an academic science meeting.